Future Forward Insights
Each of us at Nolan Heimann has an affinity for new frontiers, from immersive entertainment and influencer brands to blockchain, DAO’s, and the metaverse(s), we are attorneys with deep knowledge that provide detailed expertise in executing novel aspects of our clients’ strategies. Protecting IP, while planning for its future growth and monetization, is at the heart of what we do.
These insights are offered as an expression of our commitment to helping all creators and business makers structure their ventures on solid, authentic foundations to enable growth and transformation. Keep up-to-date with our monthly newsletter. Subscribe at the bottom of our site.
Patenting for Inventors Ep. 150 - What is Obviousness? A “Reasonable Expectation of Success” or “Predictable Results”?
Obviousness is a crucial factor in patent law, particularly in biotech. In this episode, host Adam Diament explores Vanda Pharmaceuticals v. Teva Pharmaceuticals, a case that established the reasonable expectation of success standard for determining obviousness.
The ruling invalidated Vanda’s patent for Hetlioz, and when the Supreme Court declined to review the case, the Federal Circuit’s decision became law. What does this mean for future biotech patents? Tune in as Diament breaks down the impact of this ruling and why obviousness remains one of the most challenging issues in patent law.